Finding a Safe Dose of Rhenium-186 Treatment for Young People With Ependymoma or High-Grade Glioma
Original title: Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to find a safe dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests how much of a new treatment young people with hard-to-treat brain tumors can safely take.
Who this trial is for. It tests a treatment called Rhenium-186 Nanoliposome in patients ages 6 to 21. They have ependymoma or high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary in the upper brain that came back or kept growing.
Where it stands. This trial has not reported results yet. The first part is looking for the highest dose people can safely take. A second part will use that dose. It will look at whether tumors shrink and how long before they grow again.
What this means, and what it doesn't
What it could mean: For now, this study is a way to learn if this treatment is safe for young people with these tumors. If you or your child fits, you might ask your care team about it. The trial team decides who can join.
What it doesn't mean: This is a test, not a proven treatment. Being in a trial does not mean it will help. It is not a cure, and it is not a promise of one. The right dose is not known yet.
Source: ClinicalTrials.gov, September 9, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.